 The FDA has approved Myovant Sciences Ltd NYSE: MYOV and Pfizer Incs NYSE: PFE relugolix combined with estradiol and norethindrone acetate for heavy menstrual bleeding linked to uterine fibroids in premenopausal women. The once-daily treatment will be marketed as Myfembree, with a treatment duration of up to two years. 